Researchers have identified α-KG as a key metabolite that naturally combats the pathological vasodilation and erythema associated with rosacea. By activating the OXGR1 receptor in vascular smooth muscle cells, this metabolite triggers a signaling axis that promotes vasoconstriction and reduces skin redness. Detailed cryo-EM imaging revealed a unique bipartite-acid pocket within the receptor, explaining how it recognizes specific acidic molecules like α-KG and itaconate. Using these structural insights, the team developed A-1, a highly selective and potent synthetic agonist that mimics the protective effects of α-KG. In animal models, A-1 demonstrated therapeutic efficacy similar to standard treatments like brimonidine but with a superior safety profile, avoiding common issues like rebound redness. This discovery establishes OXGR1 as a promising therapeutic target for managing chronic vascular skin disorders through metabolic modulation.

References:

• Xiao W, Zhu Y, Tang X, et al. Metabolite-gated vascular contractility switch: OXGR1 activation mechanism enables agonist therapy for rosacea erythema[J]. Cell, 2026.